FAQ on Soligenix Inc.'s HyBryte(TM) Treatment for CTCL

What is HyBryte(TM)?

HyBryte(TM) is a photodynamic therapy developed by Soligenix Inc. that uses synthetically manufactured hypericin, a highly photoactive compound, to treat early-stage Cutaneous T-cell lymphoma (CTCL).

Why is HyBryte(TM) significant for CTCL patients?

HyBryte(TM) offers a novel treatment option for CTCL, a rare and debilitating disease with limited treatment options, and has shown therapeutic potential in clinical trials, including a Phase 3 trial.

How does HyBryte(TM) work?

HyBryte(TM) works by utilizing synthetically manufactured hypericin in photodynamic therapy to target and treat malignant T-cells in the skin affected by CTCL.

Who is developing HyBryte(TM)?

HyBryte(TM) is being developed by Soligenix Inc., a late-stage biopharmaceutical company focused on rare diseases.

What recognition has HyBryte(TM) received?

HyBryte(TM) has been granted Orphan Drug Designation by both the U.S. Food and Drug Administration and the European Medicines Agency.

Where can I find more information about Soligenix and HyBryte(TM)?

More information is available in Soligenix’s newsroom at https://ibn.fm/SNGX and through BioMedWire’s coverage at https://www.biomedwire.com/.

What are the implications of HyBryte(TM) for CTCL treatment?

HyBryte(TM) represents a potential breakthrough in CTCL treatment, offering a safe and effective therapy that could significantly improve patients’ quality of life.

How can I stay updated on HyBryte(TM) and Soligenix?

To receive updates, you can follow Soligenix’s announcements in their newsroom or subscribe to BioMedWire alerts by texting ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only).